financetom
Business
financetom
/
Business
/
Blackstone tops Concord's bid for Shakira music owner Hipgnosis
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Blackstone tops Concord's bid for Shakira music owner Hipgnosis
Apr 22, 2024 1:06 AM

April 22 (Reuters) -

Blackstone made a potential offer to buy Hipgnosis

Songs Fund ( HPGSF ) for about $1.5 billion, outbidding

Apollo-backed Concord and triggering a takeover battle for the

owner of music rights by artists including Shakira and Red Hot

Chili Peppers.

Hipgnosis shares rose 10% to 1.01 pounds ($1.25) in early

trade, their highest level since September 2022. Blackstone's

fourth and latest proposal valued Hipgnosis at $1.24 per share

in cash, higher than Concord's $1.16 a share bid.

Music rights investment firm Hipgnosis said on Monday it

would recommend a higher Blackstone bid if the world's largest

private equity firm were to table a formal offer.

Blackstone is a majority owner of Hipgnosis Songs Management

(HSM), the fund's investment adviser, which holds a call option

to purchase Hipgnosis' portfolio of songs if their investment

advisory agreement was terminated.

Hipgnosis Songs Capital (HSC), a partnership between HSM

and Blackstone, owns rights to music by Justin Bieber, Nelly

Furtado and Justin Timberlake, among others.

Hipgnosis had last week agreed to the $1.4 billion deal with

Concord.

"The Board and its advisers will continue to provide

Blackstone and its advisers access to confirmatory due

diligence, to enable Blackstone to announce a firm intention to

make an offer, as soon as possible," Hipgnosis said.

Hipgnosis Songs Fund ( HPGSF ), founded by industry veteran and former

CEO Merck Mercuriadis, launched a strategic review last year

after a shareholder revolt threw its future into doubt.

The London-listed firm has since been in dispute with

HSM, which is chaired by Mercuriadis, over the call option.

Shareholders in October had rejected the fund's proposed

$440 million deal to sell 29 catalogues to HSC on valuation

concerns.

($1 = 0.8076 pounds)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Natural Gas Rises to the Highest Since 2022 As Bitter Cold in Eastern States Boosts Demand
Natural Gas Rises to the Highest Since 2022 As Bitter Cold in Eastern States Boosts Demand
Mar 11, 2026
09:28 AM EST, 01/26/2026 (MT Newswires) -- Natural gas prices surged to the highest in more than three years early on Monday as a massive winter storm brings bitter cold to the eastern half of the United States. Gas for February delivery was last seen up US$0.52, or 9.9%, to US$5.80 per million British thermal units, the highest since December,...
Municipal Bond Offerings This Week See High Flood and Hurricane Scores
Municipal Bond Offerings This Week See High Flood and Hurricane Scores
Mar 11, 2026
08:59 AM EST, 01/26/2026 (MT Newswires) -- Multiple municipal bond offerings this week have a high exposure to climate risk, specifically high Flood and Hurricane Scores, according to ICE Climate Data. A $9 million offering from East Grand Forks Public School District, Minn., records a Flood Score of 4.1 out of 5.0, ICE reports. Locations with a component Physical Climate...
LKQ explores strategic options, including sale
LKQ explores strategic options, including sale
Mar 11, 2026
Jan 26 (Reuters) - LKQ ‌Corp ​said on ‍Monday ⁠its board ⁠has ‌launched ​a review ⁠of ‍strategic ​alternatives, including a possible ‍sale of ​the ‍company. ...
LB Pharmaceuticals Initiates Phase 2 Trial of LB-102 to Treat Bipolar Depression
LB Pharmaceuticals Initiates Phase 2 Trial of LB-102 to Treat Bipolar Depression
Mar 11, 2026
08:58 AM EST, 01/26/2026 (MT Newswires) -- LB Pharmaceuticals ( LBRX ) said Monday that it has initiated a phase 2 trial evaluating the efficacy and safety of LB-102 to treat patients with bipolar depression. The biopharmaceutical company said it expects the two-arm, six-week trial to enroll approximately 320 patients with bipolar 1 depression at approximately 30 sites in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved